Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095   23/04/2024
38,97 USD (+0,67%)
(+0,67%)   23/04/2024
Grafiek Halozyme Therapeutics Inc. Grafiek Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. in het nieuws

23 april 2024 · Halozyme to Report First Quarter 2024 Financial and Operating Results · Persbericht

27 februari 2024 · Halozyme to Participate in Upcoming Investor Conferences · Persbericht

20 februari 2024 · Halozyme Reports Fourth Quarter And Full Year 2023 Financial And Operating Results · Persbericht

8 februari 2024 · Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results · Persbericht

29 januari 2024 · Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

18 januari 2024 · Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis · Persbericht

16 januari 2024 · Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

16 januari 2024 · Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types · Persbericht

12 januari 2024 · Halozyme to Host Investor Business Forum and Long-Term Outlook Call · Persbericht

6 november 2023 · Halozyme Reports Third Quarter 2023 Financial And Operating Results · Persbericht

Profiel Halozyme Therapeutics Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Helen Torley

Werknemers: 452

Aandelen Halozyme Therapeutics Inc.

Beurswaarde: 4,92 miljard USD

Effecten: 127,05 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,91

Mijn selecties